Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

doi:10.3748/wjg.v25.i18.2229

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6226)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

366

WORD

238

HTML

3841

Figures (1-2)

158

Tables (1-3)

143

Sum=4746

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

552

Download

928

Sum=1480

May 14, 2019 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. May 14, 2019; 25(18): 2229-2239
Published online May 14, 2019. doi: 10.3748/wjg.v25.i18.2229

Full Size Figure Download Figure

Figure 2 Hepatitis C virus RNA results for patients completing treatment with sustained virologic response.

Citation: Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019; 25(18): 2229-2239
URL: https://www.wjgnet.com/1007-9327/full/v25/i18/2229.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i18.2229